Patents by Inventor Jun Xian

Jun Xian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20250387402
    Abstract: The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.
    Type: Application
    Filed: June 30, 2025
    Publication date: December 25, 2025
    Inventors: Wei Peng, Jun Xian, Yonghan Hu, Yuchuan Wu, Xi Chen, Shaoqiang Huang, Xiao Liu, Xin Li, Bin Huang, Dongdong Wu
  • Polysubstituted benzene compound and preparation method and use thereof
    Patent number: 12390472
    Abstract: The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 19, 2025
    Assignee: EVOPOINT BIOSCIENCES CO., LTD.
    Inventors: Wei Peng, Jun Xian, Yonghan Hu, Yuchuan Wu, Xi Chen, Shaoqiang Huang, Xiao Liu, Xin Li, Bin Huang, Dongdong Wu
  • Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
    Patent number: 11236083
    Abstract: The present invention provides compounds of Formula (I) which can be used as SGK inhibitors; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by SGK by administering the compounds of the invention.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: February 1, 2022
    Assignee: ORIMOS THERAPEUTICS CO., LTD.
    Inventor: Jun Xian
  • POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20210308141
    Abstract: The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.
    Type: Application
    Filed: July 26, 2019
    Publication date: October 7, 2021
    Inventors: Wei Peng, Jun Xian, Yonghan Hu, Yuchuan Wu, Xi Chen, Shaoqiang Huang, Xiao Liu, Xin Li, Bin Huang, Dongdong Wu
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF
    Publication number: 20210032239
    Abstract: The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
    Type: Application
    Filed: November 24, 2017
    Publication date: February 4, 2021
    Inventor: Jun Xian
  • Small molecule inhibitors of USP1 deubiquitinating enzyme activity
    Patent number: 10653676
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: May 19, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Methods, compounds, and compositions for inhibition of ROS
    Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY
    Publication number: 20170202810
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Application
    Filed: November 3, 2016
    Publication date: July 20, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Phosphatidylcholine transfer protein inhibitors
    Patent number: 9556129
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 31, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Small molecule inhibitors of USP1 deubiquitinating enzyme activity
    Patent number: 9518032
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: December 13, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS
    Publication number: 20160031890
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Application
    Filed: March 14, 2013
    Publication date: February 4, 2016
    Inventors: Dorre A. GRUENEBERG, Ori KALID, Jun XIAN, Sharanappa B. RAJUR, Hwa-ok KIM, Venugopal Rao NEELAGIRI, Paresh GAONKAR, Divakaramenon MADHAVAN, Chaeho MOON, Madhavi NEELAGIRI
  • Phosphatidylcholine Transfer Protein Inhibitors
    Publication number: 20150336902
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Application
    Filed: July 29, 2015
    Publication date: November 26, 2015
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Phosphatidylcholine transfer protein inhibitors
    Patent number: 9126938
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: September 8, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY
    Publication number: 20130253005
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Application
    Filed: April 29, 2011
    Publication date: September 26, 2013
    Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
    Publication number: 20130231360
    Abstract: The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
    Type: Application
    Filed: April 21, 2011
    Publication date: September 5, 2013
    Applicant: THE BRIGHAM AND WOMEN S HOSPITAL, INC.
    Inventors: Jonathan Higgins, Debasis Patnaik, Natalia Ulyanova, Ross L. Stein, Jun Xian, Marcie Glicksman, Gregory D. Cuny
  • Acridines As Inhibitors Of Haspin And DYRK Kinases
    Publication number: 20130102627
    Abstract: The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
    Type: Application
    Filed: April 8, 2011
    Publication date: April 25, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jonathan Higgins, Gregory D. Cuny, Marcie Glicksman, Debasis Patnaik, Maxime Robin, Ross L. Stein, Jun Xian
  • Phosphatidylcholine Transfer Protein Inhibitors
    Publication number: 20120264756
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Application
    Filed: August 17, 2010
    Publication date: October 18, 2012
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Compositions and Methods for Inhibiting Tumor Growth
    Publication number: 20120208204
    Abstract: The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells.
    Type: Application
    Filed: June 3, 2010
    Publication date: August 16, 2012
    Applicants: The Brigham and Women's Hospital, Inc., Peresident and Fellows of Harvard College
    Inventors: Amy Baldwin, Dorre Grueneberg, Ed Harlow, Jun Xian, Karl Munger, Karin Hellner, Marcie Glicksman, Ross Stein, Gregory Cuny